medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 1

<< Back Next >>

Ann Hepatol 2011; 10 (1)

Relation of osteocalcin with insulin resistance and histopathological changes of non alcoholic fatty liver disease

Aller R, Perez CJL, de Luis DA, Conde R, Izaola O, González SM, Velasco MC, Alvarez T, Pacheco D

Language: English
References: 22
Page: 50-55
PDF size: 52.43 Kb.


ABSTRACT

Background. Osteocalcin is a hormone with a complex cross-talk between adipose tissue and the skeleton. The aim of the present study was to explore the relation of osteocalcin with histopathological changes of NALFD patients. Subjects. A population of 69 NAFLD patients was analyzed. A liver biopsy was realized. Weight, fat mass, body mass index, basal glucose, insulin, insulin resistance (HOMA), total cholesterol, LDLcholesterol, HDL-cholesterol, triglycerides and osteocalcin levels were measured. Results. Patients were divided in two groups by median osteocalcin value (11.34 ng/mL), group I (patients with the low values) and group II (patients with the high values). Only liver fibrosis frequencies were different between groups (group I: 22.9% vs group II: 9.4%; p ‹ 0.05). Patients in group I had higher levels of glucose (115.6 ± 28.1 mg/ dL vs. 103.7 ± 24.3 mg/dL; p ‹ 0.04), HOMA (4.6 ± 3.1 units vs. 3.6 ± 1.8 units; p ‹ 0.04), weight (102.9 ± 32.4 kg vs. 85.9 ± 16.8 kg; p = 0.002) and body mass index (38.3 ± 11.4 kg/m2 vs. 30.1 ± 5.7 kg/m2; p = 0.001)) than patients in group II. Osteocalcin was inverse correlated with glucose (r =-0.4; p = 0.002) and HOMA (r = -0.3:p = 0.01). Conclusion. Osteocalcin is associated with liver fibrosis. However, this association disappeared in a multivariate analysis, and HOMA remained as an independent factor.


REFERENCES

  1. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chemistry 2004; 50: 1511-25.

  2. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends in Endocrinology and Metabolism 2009; 19: 161-6.

  3. Hauschka PV. Osteocalcin and matrix Gla protein :vitamin K dependent proteins in bone. Physiol Rev 1989; 69: 990-1047.

  4. Price PA. Gla-containing proteins of bone. Connect Tissue Res 1989; 21: 51-7.

  5. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, COnfavreux C, DAcquin R, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130: 456-69.

  6. George J, Ganesh HK, Acharya S, Bandgar T, Shivane V, Karvat A, et al. Bone mineral density and disorders of mineral metabolis in chronic liver disease. W J Gastroenterology 2009; 15: 3516-22.

  7. Pietschmann P, Resch H, Muller Ch, Woloszczuk W, Willnonseder R. Decreased serum ostoecalcin levels in patients with liver cirrhosis. Bone and mineral 1990; 8: 103-8.

  8. Ludwig J, Viggiano TR, McGill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiencies with a hitherto unnamed disease. Mayo Clinic Proc 1980; 55: 434-8.

  9. Standards of medical carein Diabetes 2007. Diabetes Care 2008; 30: s4-s41.

  10. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher Df. Homesotasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-14.

  11. Pichard C, Slosman D, Hirschel B, Kyle U. Bioimpedance analysis in patients: an improved method for nutritional follow up. Clin Res 1993; 41: 53Ş.

  12. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.

  13. Bondini S, Kleiner DE, Goodman ZD, Gramlich T, Younossi ZM. Pathologic assesment of non-alcoholic fatty liver disease. Clin Liver Dis 2007; 11: 17-23.

  14. Venturi C, Zoppini G, Zamboni C, Muggeo M: Insulin sensivity and hepatic steatosis in obese subjects with normal glucose tolerance. Nutr Metab Cardiovsc Dis 2004: 14: 200-4.

  15. Browning JD, Horton JD: Molecular mediators of hepatic steatosis and liver injury. The J of Clin Invest 2004: 114: 147-52.

  16. Kindblom JM, Ohlsson C, Ljunggren O, Karlsson M, Tivesten A, Smith U, Mellstrom D. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J of Bone and Mineral Research 2009; 24: 785-91.

  17. Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporosis Int 2005; 16: 1506-12.

  18. Khosla S, Atkinson EJ, Riggs BL, Melton LJ. Relationship between body composition and bone mass in women. J Bone Miner Res 1996; 11: 857-63.

  19. Pittas A, Harris S, ELiades M, Stark P, Dawson B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrin Metab 2008 as doi:10.1210/ jc.2008-1422.

  20. Szalay F, Lakatos P, Németh J, Abonyi M, Büki B, Tarján G, Holló I. Decreased serum osteocalcin level in non-alcoholic and alcoholic chronic liver diseases. Orv Hetil 1991; 132(24): 1301-5.

  21. Feron M, Hinoi E, KArsenty G, Ducy P. Osteocalcin differentally regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild type mice. Proc Natl Acad Sci USA 2008; 105: 5266-70.

  22. Saleem U, Mosley TH Jr, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 2010; 30(7): 1474-8.




2020     |     www.medigraphic.com